Stock REPL REPLIMUNE GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
7.11 USD +27.88% Intraday chart for Replimune Group, Inc. +39.41% -15.66%
Jun. 06 Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Jun. 06 Sector Update: Health Care MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care
MT
Replimune Shares Rise as Study Data on Melanoma Treatment Improves
MT
Replimune : Primary Analysis of the IGNYTE Registrational Cohort Presentation June 2024
PU
Transcript : Replimune Group, Inc. - Special Call
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
AQ
Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma
CI
Replimune : IGNYTE Oral Presentation at ASCO 2024
PU
Replimune : RP2 Uveal Melanoma Oral Presentation at ASCO 2024
PU
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
CI
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
AQ
Replimune : Corporate Presentation May 2024
PU
Replimune Group Provides Interim Results for Skin Cancer Therapy
MT
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
AQ
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Replimune : Uveal Melanoma Biomarker Poster at AACR 2024
PU
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REPL Stock
  4. News Replimune Group, Inc.